The effects and efficacy of Tivozanib

Tivozanib is used to treat advanced kidney cancer in adults after at least two other cancer treatments did not work or had stopped working. The treatment cycle of tivozanib is 28 days, and patients may only need to use the drug for the first 21 days of each cycle. The doctor will decide how long to treat with this drug. Tivozanib, formerly known as AV-951 or KRN-951, is an oral, potent, selective VEGFR TKI with weak off-target effects and greater inhibition of VEGFRs than other TKIs previously used in metastatic renal cell carcinoma (mRCC).

Tivozanib inhibits growth factor receptors and treats renal cell carcinoma. Tivozanib inhibits tumor angiogenesis, tumor growth, and vascular permeability in mice and rats. Clinical trials have shown that tivozanib often causes hypertension; hypertension must be controlled before starting treatment. Cardiac QT interval prolongation was reported in a cardiac safety study of tivozanib, but these reactions were not clinically serious. In clinical studies, serum soluble VEGFR2 (sVEGFR2) levels decrease over time, and this effect increases with tivozanib exposure, and sVEGFR2 can serve as a pharmacodynamic marker of VEGFR inhibition.

The original drug Tivozanib has not yet been marketed in the country, so it has not been included in medical insurance. The European version of tivozanib Original drug, specifications1340mcg*21 pills sold overseas may cost around 30,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively expensive. There is currently no generic version of tivozanib available on the market. For more drug information and specific prices, please consult a medical consultant.